Targeted modulation of E3 ligases using engineered ubiquitin variants

Area of Science:

• Biochemistry
• Molecular Biology
• Cellular Biology

Background:

• Ubiquitination is a key post-translational modification regulating cellular processes.
• E3 ubiquitin ligases are critical determinants of ubiquitination specificity and are implicated in human diseases like cancer.
• Targeting E3 ligase activity is essential for disease research and drug discovery.

Purpose of the Study:

• To summarize advancements in using protein engineering to develop ubiquitin variant (UbV) based modulators for E3 ligases.
• To present UbV inhibitors for all major E3 ligase families.
• To introduce UbV activators for specific E3 ligase types.

Main Methods:

• Protein engineering of ubiquitin variants (UbVs).
• Development of UbV-based inhibitors targeting diverse E3 ligase families.
• Design of UbV-based activators for homologous with E6-associated protein C terminus (HECT) E3s and homodimeric RING E3s.

Main Results:

• Successful generation of UbV inhibitors applicable to a broad range of E3 ligases.
• Development of UbV activators for HECT and homodimeric RING E3s.
• Demonstration of a general strategy for modulating E3 ligase activity.

Conclusions:

• UbV-based molecules provide a versatile toolkit for inhibiting or activating E3 ligases.
• These synthetic molecules hold significant potential for exploring protein degradation pathways in drug discovery.
• The protein engineering approach offers a promising avenue for therapeutic development targeting E3 ligase dysfunction.